Celldex to End Phase 2 Study for Skin-disease Treatment

Dow Jones07-22

Celldex will discontinue a phase 2 study of a skin-disease treatment after it failed to meet its primary or key secondary endpoints.

The treatment, a subcutaneous delivery of barzolvolimab to treat the skin disease prurigo nodularis, did not result in an improvement in itch or skin lesions compared to a placebo, Celldex said Tuesday.

Shares fell 6%, to $33.52, in after-hours trading on Tuesday.

"It is disappointing that this study did not confirm the promising signal we observed in the intravenous Phase 1b trial, and that the robust tryptase reductions seen in this study did not result in improvement of PN symptoms for patients who greatly need effective treatments," Chief Executive Officer Anthony Marucci said.

The company said it continues to evaluate barzolvolimab to treat three other conditions: chronic spontaneous urticaria, symptomatic dermographism and cold urticaria, Marucci said.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

July 21, 2026 16:23 ET (20:23 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2653826783?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 04:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653826783","market":"us","top_or_hot":-1,"title":"Celldex to End Phase 2 Study for Skin-disease Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Celldex will discontinue a phase 2 study of a skin-disease treatment after it failed to meet its primary or key secondary endpoints. \n</p>\n<p>\n  The treatment, a subcutaneous delivery of barzolvolimab to treat the skin disease prurigo nodularis, did not result in an improvement in itch or skin lesions compared to a placebo, Celldex said Tuesday. \n</p>\n<p>\n  Shares fell 6%, to $33.52, in after-hours trading on Tuesday. \n</p>\n<p>\n  \"It is disappointing that this study did not confirm the promising signal we observed in the intravenous Phase 1b trial, and that the robust tryptase reductions seen in this study did not result in improvement of PN symptoms for patients who greatly need effective treatments,\" Chief Executive Officer Anthony Marucci said. \n</p>\n<p>\n  The company said it continues to evaluate barzolvolimab to treat three other conditions: chronic spontaneous urticaria, symptomatic dermographism and cold urticaria, Marucci said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 21, 2026 16:23 ET (20:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Celldex to End Phase 2 Study for Skin-disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCelldex to End Phase 2 Study for Skin-disease Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-22 04:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Celldex will discontinue a phase 2 study of a skin-disease treatment after it failed to meet its primary or key secondary endpoints. \n</p>\n<p>\n  The treatment, a subcutaneous delivery of barzolvolimab to treat the skin disease prurigo nodularis, did not result in an improvement in itch or skin lesions compared to a placebo, Celldex said Tuesday. \n</p>\n<p>\n  Shares fell 6%, to $33.52, in after-hours trading on Tuesday. \n</p>\n<p>\n  \"It is disappointing that this study did not confirm the promising signal we observed in the intravenous Phase 1b trial, and that the robust tryptase reductions seen in this study did not result in improvement of PN symptoms for patients who greatly need effective treatments,\" Chief Executive Officer Anthony Marucci said. \n</p>\n<p>\n  The company said it continues to evaluate barzolvolimab to treat three other conditions: chronic spontaneous urticaria, symptomatic dermographism and cold urticaria, Marucci said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 21, 2026 16:23 ET (20:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2653826783","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653826783","pubTimestamp":1784665380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Celldex will discontinue a phase 2 study of a skin-disease treatment after it failed to meet its primary or key secondary endpoints.The treatment, a subcutaneous delivery of barzolvolimab to treat the skin disease prurigo nodularis, did not result in an improvement in itch or skin lesions compared to a placebo, Celldex said Tuesday.Shares fell 6%, to $33.52, in after-hours trading on Tuesday.\"It is disappointing that this study did not confirm the promising signal we observed in the intravenous Phase 1b trial, and that the robust tryptase reductions seen in this study did not result in improvement of PN symptoms for patients who greatly need effective treatments,\" Chief Executive Officer Anthony Marucci said.The company said it continues to evaluate barzolvolimab to treat three other conditions: chronic spontaneous urticaria, symptomatic dermographism and cold urticaria, Marucci said.Write to Elias Schisgall at elias.schisgall@wsj.com Dow Jones NewswiresJuly 21, 2026 16:23 ET Copyright","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CLDX":"塞德斯医疗"},"translate_title":"Celldex 将结束皮肤病治疗的 2 期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLDX":0.9},"content_text":"Celldex will discontinue a phase 2 study of a skin-disease treatment after it failed to meet its primary or key secondary endpoints. \n\n\n  The treatment, a subcutaneous delivery of barzolvolimab to treat the skin disease prurigo nodularis, did not result in an improvement in itch or skin lesions compared to a placebo, Celldex said Tuesday. \n\n\n  Shares fell 6%, to $33.52, in after-hours trading on Tuesday. \n\n\n  \"It is disappointing that this study did not confirm the promising signal we observed in the intravenous Phase 1b trial, and that the robust tryptase reductions seen in this study did not result in improvement of PN symptoms for patients who greatly need effective treatments,\" Chief Executive Officer Anthony Marucci said. \n\n\n  The company said it continues to evaluate barzolvolimab to treat three other conditions: chronic spontaneous urticaria, symptomatic dermographism and cold urticaria, Marucci said. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 21, 2026 16:23 ET (20:23 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653826783","isCrawlerRequest":true}